Amylyx to Remove ALS Drug Relyvrio from Market, Cut Staff by 70%
TL;DR Summary
Amylyx Pharmaceuticals will remove its ALS drug Relyvrio from the market in the U.S. and Canada after a Phase 3 study involving 664 people failed to show a benefit. The decision will also lead to a 70% reduction in staff. Relyvrio had received FDA approval in 2022, but its efficacy was a subject of contention, with regulators initially advising against its approval until further testing was conducted.
- Amylyx to pull ALS drug from market, cut 70% of staff STAT
- A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says The New York Times
- Amylyx will remove ALS drug from the market after failed trial - The Washington Post The Washington Post
- ALS drug will be pulled from US market after study showed patients didn't benefit ABC News
- Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy Business Wire
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 1 min read
Condensed
64%
187 → 67 words
Want the full story? Read the original article
Read on STAT